Monday, October 17, 2005

Elan reveals favourable drug trials for key MS drug

http://tinyurl.com/b84zl


Two scientists examine human brain functions.  Irish pharmaceuticals giant Elan said that the latest tests on patients receiving its multiple sclerosis drug 'Tysabri' resulted in no new cases of a rare and frequently fatal infection.(AFP/DDP/File/Jens Schlueter)

AFP/DDP/File Photo: Two scientists examine human brain functions. Irish pharmaceuticals giant Elan said that the latest...



Tysabri, made by the Irish drugs firm and US partner Biogen, was withdrawn in February after confirmed cases of progressive multifocal leukoencephalopathy (PML), a very rare and usually fatal disease.

"Three confirmed cases of PML were previously reported, two of which were fatal," Elan said.

Findings from their latest safety tests showed "no new confirmed cases" of the infection.

The two companies submitted Tysabri to the US

Food and Drug Administration

" type="hidden"> SEARCH
News | News Photos | Images | Web

" type="hidden">
Food and Drug Administration at the end of last month, while the European Medicines Agency was also reviewing their application, the statement added.

http://news.yahoo.com/s/afp/20051017/hl_afp/irelandhealthpharmabiotechcompanyproductelan_051017110049

0 Comments:

Post a Comment

<< Home